Abstract
The 5th annual Bone and The Oncologist New Updates (bonus 5) conference, held at the National Arts Center, Ottawa, April 8–9, 2010, focused on innovative research into the mechanisms and consequences of increased bone turnover in the benign and metastatic settings alike. This year there was also a debate over the controversial use of bisphosphonates as an adjuvant treatment in patients with early-stage breast cancer. This meeting report highlights a few of the topics presented.